RxDoctor Payments Data

Tonya Alexander, PA

Physician Assistant · Portsmouth, VANPI 1245495548

Payments from drug & device makers

$4,029in general payments, 2019–2025

Across 271 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Supernus Pharmaceuticals, Inc.$809
  • Otsuka America Pharmaceutical, Inc.$538
  • Johnson & Johnson$378
  • Lundbeck LLC$148
  • Neurocrine Biosciences, Inc.$146
  • plus $631 from 15 others

What the payments were for

  • Food & beverage$4,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,029 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$75,435
Medicare patients
222
Services billed
928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole41$80,664
Invega SustennaPaliperidone Palmitate11$36,130
VraylarCariprazine Hcl16$25,252
Lurasidone Hcl153$19,461
Lamotrigine ErLamotrigine47$18,037
Aripiprazole90$12,041
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine196$6,749
Atomoxetine Hcl22$5,642
Desvenlafaxine Succinate ErDesvenlafaxine Succinate51$4,540
Divalproex Sodium ErDivalproex Sodium51$4,213
Lisdexamfetamine Dimesylate17$3,774
Olanzapine151$3,571
Bupropion XlBupropion Hcl103$3,359
Venlafaxine Hcl ErVenlafaxine Hcl120$2,641
Clonazepam251$2,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$538$80,66441 claims
Johnson & JohnsonInvega Sustenna$378$36,13011 claims
AbbVieVraylar$1,379$25,25216 claims
Almatica Pharma LLCSertraline Hcl$46$1,732188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Portsmouth

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →